发明申请
US20120244163A1 BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF
审中-公开
指导IGF-1R和ERBB3信号的双重结合剂及其用途
- 专利标题： BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF
- 专利标题（中）： 指导IGF-1R和ERBB3信号的双重结合剂及其用途
-
申请号： US13443660申请日： 2012-04-10
-
公开(公告)号： US20120244163A1公开(公告)日： 2012-09-27
- 发明人: Birgit SCHOEBERL , Ulrik NIELSEN , Arthur J. KUDLA , Arumugam MURUGANANDAM , David BUCKLER , Alexey Alexandrovich LUGOVSKOY , Jonathan Basil FITZGERALD , Lihui XU , Neeraj KOHLI
- 申请人： Birgit SCHOEBERL , Ulrik NIELSEN , Arthur J. KUDLA , Arumugam MURUGANANDAM , David BUCKLER , Alexey Alexandrovich LUGOVSKOY , Jonathan Basil FITZGERALD , Lihui XU , Neeraj KOHLI
- 申请人地址： US MA Burlington US MA Cambridge
- 专利权人： DYAX CORP.,MERRIMACK PHARMACEUTICALS, INC.
- 当前专利权人： DYAX CORP.,MERRIMACK PHARMACEUTICALS, INC.
- 当前专利权人地址： US MA Burlington US MA Cambridge
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; C12N5/09 ; C07K19/00 ; A61N5/10 ; C12P21/00 ; A61K38/02 ; A61P35/00 ; C12N5/10 ; C12N15/62
摘要：
Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.
信息查询
